VLTS 934

Drug Profile

VLTS 934

Alternative Names: PINC polymer; Poloxamer

Latest Information Update: 14 Jul 2006

Price : $50

At a glance

  • Originator Valentis
  • Class Vascular disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Peripheral arterial occlusive disorders

Most Recent Events

  • 14 Jul 2006 Results from a phase IIb clinical trial in patients with intermittent claudication have been added to the adverse events and Vascular Disorders therapeutic trials sections
  • 11 Jul 2006 Discontinued - Phase-II for Peripheral arterial occlusive disorders in USA (unspecified route)
  • 16 Feb 2006 Valentis has completed enrolment in the phase IIb trial for Peripheral arterial disease in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top